Intensity Therapeutics(US:INTS) Prnewswire·2026-01-13 12:47Core Insights - Intensity Therapeutics, Inc. is positioned for growth in 2026 following key milestones achieved in 2025, including clinical validations and a strengthened balance sheet [1][3][4] Clinical Developments - The INVINCIBLE-4 Study, a Phase 2 trial, showed a pathological complete response in the first patient and favorable safety results, with 50% fewer grade 3 or higher adverse events compared to standard care [2] - The INVINCIBLE-3 Study, a Phase 3 trial, paused new patient enrollments due to funding constraints but continues to treat existing patients and plans to reinitiate enrollment in 2026 once funding is secured [2] - A potential new Phase 3 breast cancer study may be initiated, contingent on funding and positive trends from the INVINCIBLE-4 Study [2] Financial Position - The company raised over $20 million in gross proceeds during 2025, strengthening its balance sheet and extending its operational runway into the second quarter of 2027 [3][7] - The company aims to maintain a disciplined operating approach and may seek additional capital in 2026 to support ongoing and new studies [7] Research and Publications - A peer-reviewed publication in the Lancet journal eBioMedicine reported a 75% disease control rate and median overall survival of 11.9 months for patients with advanced solid tumors, reinforcing the clinical potential of INT230-6 [2][4] - The company plans to pursue an aggressive publication strategy for its completed studies throughout 2026 [2] Product Information - INT230-6 is designed for direct intratumoral injection and combines two potent anti-cancer agents, cisplatin and vinblastine sulfate, with a diffusion enhancer, leading to localized tumor control and systemic immune engagement [5][6]